» Authors » Juan Fabregat

Juan Fabregat

Explore the profile of Juan Fabregat including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 388
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Busquets J, Secanella L, Carnaval T, Sorribas M, Serrano-Navidad M, Alba E, et al.
Cir Esp (Engl Ed) . 2024 Sep; 102(12):633-641. PMID: 39304131
Introduction: Embolization could increase the resectability of pancreatic tumors by supercharging visceral arterial perfusion prior to pancreatic surgery with arterial en-bloc resection. Its indications, however, are controversial. Methods: We retrospectively...
2.
Secanella L, Busquets J, Pelaez N, Sorribas M, Laquente B, Ruiz-Osuna S, et al.
Surg Oncol . 2023 Dec; 52:102027. PMID: 38113726
Introduction: Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) benefits from neoadjuvant treatment (NAT) with the intent of surgical salvage in the absence of disease progression during chemotherapy (CT) or chemoradiotherapy (CRT)....
3.
Busquets J, Secanella L, Cifre P, Sorribas M, Serrano T, Martinez-Carnicero L, et al.
Gastroenterol Hepatol . 2023 Oct; 47(5):448-456. PMID: 37827384
Introduction: Distal cholangiocarcinoma is a malignant epithelial neoplasia that affects the extrahepatic bile ducts, below the cystic duct. No relevant relationship between perioperative factors and worse long-term outcome has been...
4.
Secanella L, Busquets J, Pelaez N, Sorribas M, Laquente B, Ruiz S, et al.
Medicine (Baltimore) . 2022 Dec; 101(48):e32126. PMID: 36482640
Introduction: Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic...
5.
Bejarano N, Busquets J, Pelaez N, Secanella L, Sorribas M, Ramos E, et al.
Cir Esp (Engl Ed) . 2022 Oct; 101(8):522-529. PMID: 36283601
Introduction: The aim of our study is to assess the accumulated experience in the use of uncinatectomy (UC) as a parenchymal-sparing pancreatectomy technique. Method: We have carried out a observational...
6.
Busquets J, Lopez-Dominguez J, Gonzalez-Castillo A, Vila M, Pelaez N, Secanella L, et al.
Hepatobiliary Pancreat Dis Int . 2021 Mar; 20(5):485-492. PMID: 33753002
Background: There are no clearly defined indications for pancreas-preserving duodenectomy. The present study aimed to analyze postoperative morbidity and the outcomes of patients undergoing pancreas-preserving duodenectomy. Methods: Patients undergoing pancreas-preserving...
7.
Lopez-Dominguez J, Busquets J, Secanella L, Pelaez N, Serrano T, Fabregat J
Cir Esp (Engl Ed) . 2019 Sep; 97(9):523-530. PMID: 31563268
Introduction: Duodenal adenocarcinoma is a rare malignancy. Given the rarity of the disease, there is limited data related to resection results. The objective is to analyze results at our hospital...
8.
Mils K, Llado L, Ramos E, Escalante E, Fabregat J
Liver Transpl . 2018 Nov; 25(2):336-339. PMID: 30380200
No abstract available.
9.
Busquets J, Fabregat J, Verdaguer H, Laquente B, Pelaez N, Secanella L, et al.
Cir Esp . 2017 Oct; 95(8):447-456. PMID: 28992935
Introduction: A borderline resectable group (APBR) has recently been defined in adenocarcinoma of the pancreas. The objective of the study is to evaluate the results in the surgical treatment after...
10.
Aguero F, Forner A, Valdivieso A, Blanes M, Barcena R, Manzardo C, et al.
Liver Transpl . 2017 Feb; 23(5):645-651. PMID: 28188668
There is a lack of data on incidental hepatocellular carcinoma (iHCC) in the setting of liver transplantation (LT) in human immunodeficiency virus (HIV)-infected patients. This study aims to describe the...